Blinatumomab monotherapy (adult R/R Ph-negative B-ALL)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Components | DRUG-BLINATUMOMAB |
|---|
| ID | REG-BLINATUMOMAB-BALL-ADULT-RR |
|---|---|
| Type | Regimen |
| Status | reviewed 2026-04-29 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-BLAST-GOKBUGET-2018 SRC-NCCN-ALL-2025 |
Notes
CD19xCD3 BiTE for R/R Ph-negative B-ALL in adults. TOWER (Phase III, n=405, blinatumomab vs SOC chemo, R/R B-ALL) — mOS 7.7 vs 4.0 mo (HR 0.71, p=0.012); CR/CRh 44% vs 25%; MRD-negative CR 76% vs 48% in responders. Used as bridge to allogeneic HSCT in eligible patients. Ph+ B-ALL has separate regimen (TKI ± blinatumomab combinations, e.g., dasatinib + blinatumomab GIMEMA D-ALBA). MRD+ CR1 indication uses BLAST data (separate regimen entity, future). STUB — pending TOWER trial Source ingestion (SRC-TOWER-KANTARJIAN-2017) and Co-Lead sign-off.
Used By
No reverse references found in the YAML corpus.